Inactivation of Osteoblast PKC Signaling Reduces Cortical Bone Mass and Density and Aggravates Renal Osteodystrophy in Mice with Chronic Kidney Disease on High Phosphate Diet

Bone and bone derived factors in kidney disease

Purpose of review: Mineral and bone disorder (MBD) is a prevalent complication in chronic kidney disease (CKD), significantly impacting overall health with multifaceted implications including fractures, cardiovascular events, and mortality. Despite its pervasive nature, effective treatments for CKD-MBD are lacking, emphasizing the urgency to advance understanding and therapeutic interventions. Bone metabolism intricacies, influenced by factors like 1,25 dihydroxy vitamin D, parathyroid hormone (PTH), and fibroblast growth factor 23 (FGF23), along with intrinsic osseous mechanisms, play pivotal roles in CKD. Skeletal abnormalities precede hormonal changes, persisting even with normalized systemic mineral parameters, necessitating a comprehensive approach to address both aspects. Recent findings: In this review, we explore novel pathways involved in the regulation of systemic mineral bone disease factors, specifically examining anemia, inflammation, and metabolic pathways. Special emphasis is placed on internal bone mechanisms, such as hepatocyte nuclear factor 4α, transforming growth factor-β1, and sclerostin, which play crucial roles in the progression of renal osteodystrophy. Summary: Despite advancements, effective treatments addressing CKD-MBD morbidity and mortality are lacking, necessitating ongoing research for novel therapeutic targets.

Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas

B-cell lymphomas (BCLs) are the most common disease entity among hematological malignancies and have various genetically and molecularly distinct subtypes. In this study, we revealed that the blockade of phosphoinositide-dependent kinase-1 (PDPK1), the master kinase of AGC kinases, induces a growth inhibition via cell cycle arrest and the induction of apoptosis in all eight BCL-derived cell lines examined, including those from activated B-cell-like diffuse large B-cell lymphoma (DLBCL), double expressor DLBCL, Burkitt lymphoma, and follicular lymphoma. We also demonstrated that, in these cell lines, RSK2, AKT, and S6K, but not PLK1, SGK, or PKC, are the major downstream therapeutic target molecules of PDPK1 and that RSK2 plays a central role and AKT and S6K play subsidiary functional roles as the downstream effectors of PDPK1 in cell survival and proliferation. Following these results, we confirmed the antilymphoma efficacy of TAS0612, a triple inhibitor for total RSK, including RSK2, AKT, and S6K, not only in these cell lines, regardless of disease subtypes, but also in all 25 patient-derived B lymphoma cells of various disease subtypes. At the molecular level, TAS0612 caused significant downregulation of MYC and mTOR target genes while inducing the tumor suppressor TP53INP1 protein in these cell lines. These results prove that the simultaneous blockade of RSK2, AKT, and S6K, which are the pivotal downstream substrates of PDPK1, is a novel therapeutic target for the various disease subtypes of BCLs and line up TAS0612 as an attractive candidate agent for BCLs for future clinical development.

Mouse Models of Mineral Bone Disorders Associated with Chronic Kidney Disease

Patients with chronic kidney disease (CKD) inevitably develop mineral and bone disorders (CKD–MBD), which negatively impact their survival and quality of life. For a better understanding of underlying pathophysiology and identification of novel therapeutic approaches, mouse models are essential. CKD can be induced by surgical reduction of a functional kidney mass, by nephrotoxic compounds and by genetic engineering specifically interfering with kidney development. These models develop a large range of bone diseases, recapitulating different types of human CKD–MBD and associated sequelae, including vascular calcifications. Bones are usually studied by quantitative histomorphometry, immunohistochemistry and micro-CT, but alternative strategies have emerged, such as longitudinal in vivo osteoblast activity quantification by tracer scintigraphy. The results gained from the CKD–MBD mouse models are consistent with clinical observations and have provided significant knowledge on specific pathomechanisms, bone properties and potential novel therapeutic strategies. This review discusses available mouse models to study bone disease in CKD.

Effects of Dietary Phosphorus Levels on Growth Performance, Phosphorus Utilization and Intestinal Calcium and Phosphorus Transport-Related Genes Expression of Juvenile Chinese Soft-Shelled Turtle (Pelodiscus sinensis)

A 60-day feeding trial was performed to assess the effects of dietary phosphorus levels on growth performance, body composition, phosphorus utilization, plasma physiological parameters and intestinal Ca and P transport-related gene expression of juvenile Chinese soft-shelled turtle (P. sinensis). Four diets containing available P at graded levels of 0.88%, 1.00%, 1.18% and 1.63% (termed as D0.88, D1.00, D1.18 and D1.63, respectively) were formulated and each diet was fed to turtles (5.39 ± 0.02 g) in sextuplicate. The turtles were randomly distributed to 24 tanks with 8 turtles per tank. The results indicated that final body weight, specific growth rate, feed conversion ratio and protein efficiency ratio performed best in turtles fed 1.00% available P diet. The crude lipids of the whole body exhibited a decreasing trend with the dietary available P, whereas the calcium and phosphorus of the whole body and bone phosphorus showed an opposite tendency. The apparent digestibility coefficient of phosphorus declined with the dietary available P. Turtles fed 1.00% available phosphorus had the highest phosphorus retention ratio compared with other treatments. Simultaneously they had significantly lower phosphorus loss than turtles fed D1.18 and D1.63 and had no differences in this respect from turtles fed a low-phosphorus diet. It was noteworthy that the lowest plasma calcium concentrations, and alkaline phosphatase activities in plasma and liver, were discovered in turtles fed the diet containing 1.63% available phosphorus. In addition, the high-phosphorus diet resulted in significantly down-regulated expression of intestinal phosphorus and calcium transport-related key genes. In conclusion, the available phosphorus requirement of juvenile P. sinensis was determined at 1.041% (total phosphorus was 1.80%) based on quadratic regression of weight gain rate, and excessive dietary phosphorus stunted turtle growth possibly via inhibiting intestinal calcium absorption.